Status:

COMPLETED

A Feasibility Randomised Controlled Trial of Early Vitrectomy for Post-operative Exogenous Endophthalmitis

Lead Sponsor:

Moorfields Eye Hospital NHS Foundation Trust

Collaborating Sponsors:

University College, London

King's College London

Conditions:

Endophthalmitis Postoperative Acute

Eligibility:

All Genders

18-95 years

Phase:

NA

Brief Summary

This randomised clinical trial will explore the feasibility and acceptability of carrying out early vitrectomy surgical treatment compared to standard treatment in acute endophthalmitis. We will inves...

Detailed Description

The EVIAN Study is a multicentre, feasibility, randomised controlled trial to evaluate the effect of early vitrectomy surgery on acute endophthalmitis. Patients with postoperative exogenous endophtha...

Eligibility Criteria

Inclusion

  • The patient over 18 years of age
  • Patient has capacity to give informed consent
  • Patient has not previously been enrolled in this study in regards to their other eye
  • Diagnosis of postoperative endophthalmitis at any time-point following an ocular surgery/procedure/injection
  • Patient is healthy to undergo vitrectomy surgery
  • Symptomatic Visual loss attributable to POE
  • Best corrected visual acuity worse than 35 ETDRS letters, including CF, HM and POL vision

Exclusion

  • Patient suffered a major thromboembolic event within the past 3 months as (defined as TIA, Stroke, or MI)
  • Known adverse reaction to intravitreal antibiotics (amikacin/vancomyin/cephalosporins)
  • Blood pressure greater than 200 systolic or 100 diastolic
  • Any other condition that in the opinion of the investigator would preclude participation in the study (such as unstable medical status or severe disease that would make it difficult for the patient to be able to complete the study)
  • The patient will use an investigational drug during the study
  • History of optic atrophy in the study eye
  • Corneal oedema/haze that would prevent visualisation of fundus to perform vitrectomy surgery
  • Patient over the age of 95 who present with POE should immediately be placed on the pre-screening log as ineligible

Key Trial Info

Start Date :

August 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 4 2025

Estimated Enrollment :

63 Patients enrolled

Trial Details

Trial ID

NCT04522661

Start Date

August 12 2021

End Date

February 4 2025

Last Update

July 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Moorfields Eye Hospital

London, United Kingdom